Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy
about
Pulmonary Hypertension and Indicators of Right Ventricular FunctionCoronary microvascular resistance: methods for its quantification in humansPrenatal hypoxia induces increased cardiac contractility on a background of decreased capillary densityMyocardial flow reserve (MFR) with positron emission tomography (PET)/computed tomography (CT): clinical impact in diagnosis and prognosis.Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy.Feasibility of subendocardial and subepicardial myocardial perfusion measurements in healthy normals with (15)O-labeled water and positron emission tomographyCarriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction.Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.Increased Klk9 Urinary Excretion Is Associated to Hypertension-Induced Cardiovascular Damage and Renal Alterations.Functional effects of a tropomyosin mutation linked to FHC contribute to maladaptation during acidosisNatural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive micePeripheral microvascular function is altered in young individuals at risk for hypertrophic cardiomyopathy and correlates with myocardial diastolic function.Insights into restrictive cardiomyopathy from clinical and animal studies.Microvascular ischemia in hypertrophic cardiomyopathy: new insights from high-resolution combined quantification of perfusion and late gadolinium enhancement.Quantitative cardiac positron emission tomography: the time is coming!Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy: Insights From Wave Intensity Analysis and Magnetic Resonance.Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis.Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: insights from positron emission tomography.Coronary microvascular dysfunction: mechanisms and functional assessment.Clinical topic: Nuclear imaging in hypertrophic cardiomyopathy.Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation.Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM).Novel biomarkers of coronary microvascular disease.Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies.Evaluation of hypertrophic cardiomyopathy: new horizons for CMR?Left ventricular outflow tract gradient is associated with reduced capillary density in hypertrophic cardiomyopathy irrespective of genotype.Left atrial enlargement increases the risk of major adverse cardiac events independent of coronary vasodilator capacity.Myocardial perfusion PET: a split function?Myocardial blood flow and adenosine A2A receptor density in endurance athletes and untrained men.Endocardial and epicardial myocardial perfusion determined by semi-quantitative and quantitative myocardial perfusion magnetic resonance.Impact of anatomical and functional severity of coronary atherosclerotic plaques on the transmural perfusion gradient: a [15O]H2O PET study.Positron emission tomography for the evaluation and treatment of cardiomyopathy.Plasma glycogen phosphorylase BB is associated with pulmonary artery wedge pressure and left ventricle mass index in patients with hypertrophic cardiomyopathy.Validation of pixel-wise parametric mapping of myocardial blood flow with 13NH3 PET in patients with hypertrophic cardiomyopathy
P2860
Q26744781-92F35F30-2EE0-4400-A417-9DBD17D5961EQ30487553-EFD4F67B-9DD6-4E43-A3B4-75DB5FB249C3Q33397848-BC9A13DF-FE85-4781-8817-58AE91F33DB1Q33651049-79D8678C-448E-4E2E-A57B-4E4480CFE656Q33872015-86978104-9D09-4528-B524-0E7EA8B4AC3CQ33881928-4DF0AC72-4089-48DB-9D99-F36DC40CA250Q34054904-2183296F-15AD-4B57-9996-E1E36C8DF3BFQ34241524-612B6362-2061-44F3-B610-80C7CF7C99A9Q34498111-A0F9264E-C059-4D62-8724-21258A2C3835Q34561038-4F5DB463-C46F-4EC1-ABE8-61E6C459E7EBQ34756142-AE6B7A44-0308-4DAF-B74A-BD923F25DFC0Q35583070-BF517C32-062E-4746-8188-5D50E0AC349CQ36077266-0D0978D3-9A75-4BFB-ABCC-95C9514CD02DQ36466791-13A72AAB-90E7-4D29-8977-A8721BB83C78Q37288099-22998784-D58F-4809-9166-1DE0318F165BQ37318366-D771D332-6722-43BD-88BE-37D8AC67403BQ37366263-92A7547D-E1EF-40E7-B240-867D493677C3Q38059853-21D03049-33BB-4A60-B0F3-501886B32909Q38259726-4C3D7EB2-7DF4-4BB2-BC44-7566CEB652CBQ38303465-8466A3B1-8558-4808-BBF9-6A1840B60D10Q38538168-9A817CBD-A594-4C23-AF05-27F5D25D0718Q38723494-0DBD7406-B506-4FD9-AFC8-90DE202FD3FBQ38854433-EFA5B80A-806E-474A-B1CF-1CA08D91A887Q39347577-DAD50AC7-9103-4393-9B3B-F558ADA566EDQ39869842-0F115A95-0FF3-4E09-BA24-8754C12A16C7Q40458508-18473CAF-30DB-4E6B-AE3D-EEE08AD126D6Q40900344-471CAD7D-B809-4AA5-80DB-64EEEF30507FQ42840270-DA0ABF4B-6CE1-40BF-9C85-B65BCB2D476DQ46388832-025A6036-5FC3-423F-94F0-E7766675B324Q52844547-12C5C7D3-C123-4703-9E8C-CD6FBFA24007Q53067640-05FB4028-C8EE-4F37-9078-EC2BC9E9F8C0Q53236739-28DCA9CA-36F1-4D72-BB5E-7CDB1ACFB56EQ55052917-6D9C0438-5621-46B7-AA6D-15B04CD181E3Q57988200-30BFBEA0-B36B-40A0-95F3-65F7248C29EE
P2860
Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy
description
article
@en
im Dezember 2007 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2008
@uk
name
Determinants of coronary micro ...... ic hypertrophic cardiomyopathy
@en
Determinants of coronary micro ...... ic hypertrophic cardiomyopathy
@nl
type
label
Determinants of coronary micro ...... ic hypertrophic cardiomyopathy
@en
Determinants of coronary micro ...... ic hypertrophic cardiomyopathy
@nl
prefLabel
Determinants of coronary micro ...... ic hypertrophic cardiomyopathy
@en
Determinants of coronary micro ...... ic hypertrophic cardiomyopathy
@nl
P2093
P2860
P50
P1476
Determinants of coronary micro ...... ic hypertrophic cardiomyopathy
@en
P2093
Albert C van Rossum
Frans C Visser
Jos W R Twisk
Jurrien M ten Berg
Marco J W Götte
Ornella E Rimoldi
Paolo G Camici
Paul Knaapen
Pieter A Dijkmans
Tjeerd Germans
P2860
P304
P356
10.1152/AJPHEART.00233.2007
P577
2007-12-21T00:00:00Z